



Corporate Office :
406, Silver Oaks Comm. Complex,
Opp. Arun Society, Paldi,
Ahmedabad-380 007. Gujarat, India.
Phone : 079-26584655
Fax : 079-26588054
CIN No. : L24231GJ2004PLC043861
E-mail : info@sakarhealthcare.com
Web : www.sakarhealthcare.com

21st November, 2023

To,
The Manager – Listing & Compliance
National Stock Exchange of India Limited
Exchange Plaza, 5th Floor Plot No. C/1,
G Block Bandra-Kurla Complex,
Bandra (East), Mumbai 400 051

Symbol: SAKAR

Subject: Outcome of Meeting of the Board of Directors of Sakar Healthcare Limited (“the Company”) in terms of Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (“SEBI LODR Regulations”)

Dear Sir / Madam,

Pursuant to Regulation 30 of the SEBI LODR Regulations, we hereby inform that the Board of Directors (“Board”) of the Company at their meeting held on Tuesday, 21st November, 2023 *inter alia* considered and approved the following:

1. Issuance of Equity Shares and Warrants by way of preferential issue to Promoter and Non-Promoter Group Categories

Subject to the approval of members / shareholders of the Company and such other regulatory/governmental authorities as may be required, the Board has approved to create, offer, issue and allot:

- up to 4,00,000 Equity shares of face value of ₹10/- (Rupees Ten only) each at an issue price of ₹384/- per equity shares; and
- up to 5,00,000 Warrants (convertible into equal number of equity shares) of face value ₹10/- (Rupees Ten only) each at an issue price of ₹384/- per Warrant

on a preferential basis (“**Preferential Issue**”) to the persons/proposed allottee(s) belonging to Promoter Group as well as to Non Promoter Categories, in accordance with the provisions of the Companies Act, 2013 and the rules made there under, Chapter V of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018 (“**SEBI ICDR Regulations**”), SEBI LODR Regulations and on such terms and conditions as maybe determined by the Board.

In accordance with Regulation 30 of Listing Regulations read with SEBI circular No.CIR/CFD/CMD/4/20 15 dated September 9, 2015 and SEBI circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated 13 July, 2023, details of the Preferential Issue are enclosed herewith and marked as **Annexure A**.

2. Approval of Notice of Extra Ordinary General Meeting (“**EGM**”) of the Company to be held on Wednesday, 20th December, 2023 through VC/OAVM, to seek necessary approvals of the members/shareholders for the Preferential Issue.



The Board Meeting commenced at 12:30 p.m. and concluded at 2:30 p.m.

The Notice of Extra Ordinary General Meeting and other relevant documents shall be submitted in due course.

Kindly take same on your record and disseminate on your website.

Thanking You,

Yours faithfully,

For SAKAR HEALTHCARE LIMITED


BHARAT SONI
COMPANY SECRETARY
COMPLIANCE OFFICER



Encl.: *Annexure A - Details of proposed preferential issue*

ANNEXURE A

DETAILS OF PROPOSED PREFERENTIAL ISSUE

Sr. No	Particulars of disclosure	Disclosure for Equity Shares	Disclosures for Warrants (convertible into equal number of equity shares)																																						
1.	Types of securities proposed to be issued	Equity shares having face value of ₹10/- per equity share ("Equity Shares").	Warrants (convertible into equal number of equity shares) having face value of ₹10/- each																																						
2.	Type of issuance	Preferential Issue	Preferential Issue																																						
3.	Total number of securities proposed to be issued or the total amount for which the securities will be issued (approximately)	Up to 4,00,000 Equity Shares of face value ₹10/- each, at an issue price of ₹384/- per share.	Up to 5,00,000 Warrants having face value of ₹10/- each, at an issue price of ₹384/- per warrant which will be convertible into equal number of equity shares within a period of 18 months from the date of allotment. Note:- - The tenure of Warrants will be 18 months. - 25% of the total consideration will be paid at the time of issuance of the warrants and the remaining 75% of the total consideration shall be paid upon the exercise/ conversion of each warrant.																																						
4.	Details to be furnished in case of preferential issue																																								
	a. Name of the investor(s)	Non Promoters: 1. Hi-Tech Chemicals Limited	Non Promoters: 1. Hi-Tech Chemicals Limited 2. Hemant Gadodia 3. Prakash Diwan 4. Sunil Kabra Promoters: 5. Sanjay Shah 6. Aarsh Shah																																						
	1. Post allotment of securities outcome of the subscription, issue price /allotted price (in case of convertibles), number of investors	Outcome of allotment: <table border="1"> <thead> <tr> <th rowspan="2">Investor</th> <th colspan="2">Pre-Issue equity shareholding</th> <th colspan="2">Proposed Post-issue Equity Shareholding*</th> </tr> <tr> <th>No.</th> <th>%</th> <th>No.</th> <th>%</th> </tr> </thead> <tbody> <tr> <td>Hi-Tech Chemicals Limited⁵</td> <td>NIL</td> <td>NIL</td> <td>4,00,000</td> <td>1.80%</td> </tr> </tbody> </table> <small>*Assuming post issuance of equity shares on fully diluted basis and all the warrants are exercised. ⁵Post allotment of Equity Shares and conversion of warrants into Equity, the total Shareholding would be 6,00,000 Equity Shares representing 2.70% of post issue capital</small>	Investor	Pre-Issue equity shareholding		Proposed Post-issue Equity Shareholding*		No.	%	No.	%	Hi-Tech Chemicals Limited ⁵	NIL	NIL	4,00,000	1.80%	Outcome of allotment: <table border="1"> <thead> <tr> <th rowspan="2">Investor</th> <th colspan="2">Pre-Issue equity shareholding</th> <th colspan="2">Proposed Post-issue Equity Shareholding*</th> </tr> <tr> <th>No.</th> <th>%</th> <th>No.</th> <th>%</th> </tr> </thead> <tbody> <tr> <td>Sanjay Shah</td> <td>99,08,543</td> <td>46.41</td> <td>1,00,08,543</td> <td>44.98%</td> </tr> <tr> <td>Aarsh Shah</td> <td>13,07,500</td> <td>6.12</td> <td>1407500</td> <td>6.33%</td> </tr> <tr> <td>Hemant Gadodia</td> <td>NIL</td> <td>NIL</td> <td>34,000</td> <td>0.15%</td> </tr> </tbody> </table>	Investor	Pre-Issue equity shareholding		Proposed Post-issue Equity Shareholding*		No.	%	No.	%	Sanjay Shah	99,08,543	46.41	1,00,08,543	44.98%	Aarsh Shah	13,07,500	6.12	1407500	6.33%	Hemant Gadodia	NIL	NIL	34,000	0.15%
Investor	Pre-Issue equity shareholding			Proposed Post-issue Equity Shareholding*																																					
	No.	%	No.	%																																					
Hi-Tech Chemicals Limited ⁵	NIL	NIL	4,00,000	1.80%																																					
Investor	Pre-Issue equity shareholding		Proposed Post-issue Equity Shareholding*																																						
	No.	%	No.	%																																					
Sanjay Shah	99,08,543	46.41	1,00,08,543	44.98%																																					
Aarsh Shah	13,07,500	6.12	1407500	6.33%																																					
Hemant Gadodia	NIL	NIL	34,000	0.15%																																					



Sr. No	Particulars of disclosure	Disclosure for Equity Shares	Disclosures for Warrants (convertible into equal number of equity shares)				
		<p>Issue Price: Equity Shares to be issued to the aforementioned allottee at a price of ₹384/- per equity share, which is not lower than the floor price i.e. INR 383.31 calculated in accordance with Regulation 164 of the SEBI ICDR Regulations.</p> <p>Number of Investors: Only one Investor (Non Promoter) is being issued Equity Shares.</p>	Prakash Diwan	20,000	0.09	53,000	0.24%
			Sunil Kabra	NIL	NIL	33,000	0.15%
			Hi-Tech Chemicals Limited ⁵	NIL	NIL	2,00,000	0.90%
			<p>* Assuming post issuance of equity shares on fully diluted basis and all the warrants are exercised.</p> <p>⁵ Post allotment of Equity Shares and conversion of warrants into Equity, the total Shareholding would be 6,00,000 Equity Shares representing 2.70% of post issue capital</p>				
			<p>Issue Price: Warrants (convertible into equal number of equity shares) to be issued to the aforementioned allottee(s) at a price of ₹384/- per warrant, which is not lower than the floor price i.e. INR 383.31 calculated in accordance with Regulation 164 of the SEBI ICDR Regulations.</p>				
			<p>Number of Investors: Six Investors (Promoters & Non Promoters) are being issued Warrants (convertible into equal number of equity shares).</p>				
	In case of convertibles - intimation on conversion of securities or on lapse of the tenure of the instrument	Not Applicable	<p>Each warrant shall be convertible into 1 (one) equity shares within a period of 18 (eighteen) months from the date of allotment in one or more tranches, as the case may be and on such other terms and conditions as applicable upon exercise of option of conversion by the warrant holder.</p> <p>25% of the total consideration will be paid at the time of issuance of the warrants and the remaining 75% of the total consideration shall be paid upon the exercise/ conversion of each warrant within a period of 18 months of allotment of warrants.</p> <p>The warrants conversion can be exercised at any time within a period of 18 months from the date of allotment, in one or more tranches, as the case may be and on such other terms and conditions as applicable.</p>				
5.	Any cancellation or termination of proposal for issuance of	Not Applicable	Not Applicable				



Sr. No	Particulars of disclosure	Disclosure for Equity Shares	Disclosures for Warrants (convertible into equal number of equity shares)
	securities Including reasons thereof		
6.	Lock in	The Equity Shares shall be subject to 'lock-in' as prescribed under the applicable provisions of the SEBI ICDR Regulations.	The Warrants and the Equity Shares upon conversion shall be subject to 'lock-in' as prescribed under the applicable provisions of the SEBI ICDR Regulations.

Thanking you,

Yours faithfully,

For SAKAR HEALTHCARE LIMITED


BHARAT SONI
COMPANY SECRETARY &
COMPLIANCE OFFICER

